Receptagen to Develop 'Growth Blocker' Monoclonal Antibody

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

SEATTLE--Receptagen Ltd. has begun formal clinical development of its first "growth blocker" drug, based on promising laboratory studies. The agent, a monoclonal antibody that blocks the B12 carrier protein trans-cobalamin II, triggered apoptosis in cancer cells by depleting vitamin B12, an essential enzyme co-factor for cell proliferation, said Receptagen president A. Charles Morgan Jr., PhD.

SEATTLE--Receptagen Ltd. has begun formal clinical developmentof its first "growth blocker" drug, based on promisinglaboratory studies. The agent, a monoclonal antibody that blocksthe B12 carrier protein trans-cobalamin II, triggered apoptosisin cancer cells by depleting vitamin B12, an essential enzymeco-factor for cell proliferation, said Receptagen president A.Charles Morgan Jr., PhD.

Articles in this issue
First Results of Avicidin Trials
Chemo Patients Often Develop Menstrual Irregularities
Growth Factor Receptor Blockade Moving From Laboratory to Clinic
Controlled-Release AZT Gets FDA Go-Ahead for New Drug Investigation
Vinorelbine Plus Chemo Promising in Advanced Disease
Bone Substudy a Part of Tamoxifen Prevention Trial
Ultrasound Breast Screens Useful in Selected Women
New Roles Forecast for Endocrine Therapy
Antisense Drug Against BCL-2 Effective in Animal Cancer Models
Anticancer Drugs From Zeneca in Regulatory Phase of Development
Osteosarcoma Chemo Regimens Debated
Primary Chemotherapy Allows Breast-Conserving Surgery in French Study
Cancer Care, Inc. Sponsors Make-Up Clinics for Chemo Patients
$2 Billion Budget for NCI Proposed
Risk of Gyn Cancer Increases After Diagnosis of Breast Cancer
Related Videos
video 8 - "Treatment Landscape for NSCLC With EGFR Exon 20 Insertion Mutations"
Video 7 - "Second-Line Treatment of Patients With EGFR-Mutated NSCLC"
A panel of 5 experts on liver cancer
A panel of 5 experts on liver cancer
A panel of 5 experts on liver cancer
A panel of 5 experts on liver cancer
Estelamari Rodriguez, MD, MPH, an expert on lung cancer
Christine Bestvina, MD, an expert on lung cancer
Caitlin Costello, MD, with the Oncology Brothers
Related Content
Phase 2 data support the potential of replacing cisplatin with nab-paclitaxel as a backbone therapy for those with muscle-invasive bladder cancer.

Nivolumab Combo Shows Efficacy, Safety in Muscle-Invasive Bladder Cancer

May 10th 2024
Article

Phase 2 data support the potential of replacing cisplatin with nab-paclitaxel as a backbone therapy for those with muscle-invasive bladder cancer.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

May 6th 2024
Podcast

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

FDA Grants Fast Track Designation to SNB-101 in Small Cell Lung Cancer

FDA Grants Fast Track Designation to SNB-101 in Small Cell Lung Cancer

May 10th 2024
Article

Treatment with SNB-101 previously demonstrated tolerability among patients with solid tumors in a phase 1 trial.

Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

Applying Novel Radiotherapy Technology for Brain Tumors and Other Cancers

April 29th 2024
Podcast

Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

Investigators found that imatinib maintenance therapy for 6 years reduced the risk of recurrence in patients with gastrointestinal stromal tumors.

Six-Year Imatinib Maintenance Therapy Reduces Recurrence Risk in GIST

May 9th 2024
Article

Investigators found that imatinib maintenance therapy for 6 years reduced the risk of recurrence in patients with gastrointestinal stromal tumors.

Phase 2 data support the use of fuzuloparib with or without apatinib in HER2-negative metastatic breast cancer harboring BRCA1/2 germline mutations.

Fuzuloparib ± Apatinib Improves PFS in BRCA+ Metastatic Breast Cancer

May 9th 2024
Article

Phase 2 data support the use of fuzuloparib with or without apatinib in HER2-negative metastatic breast cancer harboring BRCA1/2 germline mutations.